Adaptimmune Therapeutics plc American Depositary Shares
Symbol: ADAP (NASDAQ)
0.35
▲ (3.82%) 0.013
Company Description:
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Key Stats
- Today's Open: $0.3306
- Today's High: $0.37
- Today's Low: $0.329
- Today's Volume: 1.11M
- Yesterday Close: $0.3323
- Yesterday High: $0.3578
- Yesterday Low: $0.2979
- Yesterday Volume: 3.67M
- Last Min Volume: 0
- Last Min High: $0.345
- Last Min Low: $0.343
- Last Min VWAP: $0
Company Profile
- Name: Adaptimmune Therapeutics plc American Depositary Shares
- Website: https://www.adaptimmune.com
- Listed Date: 2015-05-06
- Location: ABINGDON, OXFORDSHIRE, X0
- Market Status: Active
- CIK Number: 0001621227
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $88.08M
- Round Lot: 100
- Outstanding Shares: 265.05M
- Asset Type: ADRC
RECENT FILINGS FOR ADAP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-17 | 8-K | View |
| 2025-05-29 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 8-K | View |
| 2025-05-01 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-18 | S-3 | View |
| 2025-04-15 | PRE 14A | View |
| 2025-04-14 | 8-K | View |
| 2025-03-24 | 10-K | View |
| 2025-03-24 | 8-K | View |
| 2025-03-20 | 8-K | View |
| 2025-02-20 | 4 | View |
| 2025-02-20 | 4 | View |
| 2025-02-20 | 4 | View |
| 2025-02-20 | 4 | View |
| 2025-02-20 | 4 | View |
| 2025-02-20 | 4 | View |
Latest News on ADAP